Therapeutic Uses
Anti-Parkinsons
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Piribedil-d8 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Piribedil-d8 usage and description
Piribedil D8 is a deuterated form of Piribedil, a dopamine D2 receptor agonist used for the treatment of Parkinson's disease. This deuterated form is used in pharmacokinetic research to study the metabolism, distribution, and excretion of Piribedil.
The chemical formula of Piribedil D8 is C16H11D8N3O, with a molecular weight of 267.37 g/mol. It is a white to off-white powder with a purity of ≥98% and a deuterium enrichment of ≥98%.
Piribedil D8 binds to dopamine receptors in the brain, stimulating the release of dopamine and improving the symptoms of Parkinson's disease such as tremors, rigidity, and slow movement. This medication also has vasodilatory properties, which can improve blood flow to the brain and reduce the risk of stroke.
The recommended dosage of Piribedil D8 varies depending on the severity of Parkinson's disease and the patient's response to treatment. Common side effects include nausea, dizziness, and headache. Piribedil D8 may interact with other medications, so it is important to inform the doctor of all medications taken.
In conclusion, Piribedil D8 is a useful tool for studying the pharmacokinetics of Piribedil and has therapeutic potential in the treatment of Parkinson's disease.
